Group 1 - The core viewpoint of the news is that Yinno Pharmaceutical is set to launch its IPO on the Hong Kong Stock Exchange, focusing on its weight loss drug and raising approximately HKD 610 million for clinical trials and commercialization [1][2] - The company plans to issue 36.56 million shares at a price of HKD 18.68 per share, with 10% allocated for public offering in Hong Kong and the remainder for international investors [1] - Major cornerstone investors include Junsheng, Maifushi, Ginkgo Fund, and others, committing a total of USD 10 million (approximately HKD 78.5 million) [1] Group 2 - Established in 2014, Yinno Pharmaceutical specializes in innovative therapies for diabetes and metabolic diseases, with its lead product, Isupatide α, targeting obesity and related conditions [2] - The company has recently ended a decade of zero revenue, with Isupatide α approved for treating type 2 diabetes, generating revenue of approximately CNY 38.14 million in the first five months of 2025 [2] - For the fiscal years 2023 and 2024, the company reported R&D expenses of CNY 492 million and CNY 103 million, with corresponding losses of CNY 733 million and CNY 175 million [2]
又一减肥概念股即将登陆港股市场 晶泰控股为其基石投资者
Zheng Quan Shi Bao Wang·2025-08-08 23:12